TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8814628

Group type: EXPERIMENTAL
Intervention: Lubricated dowels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-lubricated dowels
Number of subjects: 0
Study: 1465591

Group type: EXPERIMENTAL
Intervention: Norfloxacin (active drug)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 60
Study: 6437343

Group type: EXPERIMENTAL
Intervention: Postoperative administration of FT‐207 suppository (Group A)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative administration of FT‐207 suppository (Group B)
Number of subjects: 72
Study: 31513262

Group type: EXPERIMENTAL
Intervention: Presence of a Cilioretinal Artery (CRA) in fellow eyes without baseline CNV
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Presence of a Cilioretinal Artery (CRA) in study eyes with baseline CNV
Number of subjects: 350
Study: 29684647

Group type: EXPERIMENTAL
Intervention: BATHE intervention (Background, Affect, Trouble, Handling, Empathy) used by trained GPs
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Top-up trainings based on CA analysis
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CA methods for assessing implementation fidelity
Number of subjects: 21
Study: 26709596

Group type: EXPERIMENTAL
Intervention: Modified-release (MR) formulations of omecamtiv mecarbil (25 mg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Immediate-release (IR) formulation of omecamtiv mecarbil (25 mg)
Number of subjects: 65
Study: 24828092

Group type: COMPARATOR
Intervention: Conventional subunit vaccine (Agrippal S1; Novartis)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine (Fluad; Novartis)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Intradermal vaccine (IDflu15; Sanofi Pasteur)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Conventional subunit vaccine
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Intradermal vaccine
Number of subjects: 335
Study: 22183975

Group type: EXPERIMENTAL
Intervention: Aggressive treatment (methotrexate 0.5 mg/kg/week, etanercept 0.8 mg/kg/week, prednisolone 0.5 mg/kg/day tapered to 0 by 17 weeks)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Methotrexate (same dosage as arm 1), etanercept placebo, and prednisolone placebo
Number of subjects: 85
Study: 20573974

Group type: EXPERIMENTAL
Intervention: Congruent condition (ipsilateral response)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incongruent condition (contralateral response)
Number of subjects: 0
Study: 17760981

Group type: EXPERIMENTAL
Intervention: Standardised physiotherapy treatment of advice and exercises for the arm and shoulder for three months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Leaflet containing advice and exercises (Control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standardised physiotherapy treatment
Number of subjects: 30
Study: 15013248

Group type: EXPERIMENTAL
Intervention: bupropion SR 300 mg/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study: 12146772

Group type: EXPERIMENTAL
Intervention: Sustained Achilles tendon stretches (3 minutes, 3 times daily)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Intermittent Achilles tendon stretches (5 sets, 20 seconds each, 2 times daily)
Number of subjects: 94
Study: 9659323

Group type: EXPERIMENTAL
Intervention: Casualty officers interpreting images
Number of subjects: 25

Group type: COMPARATOR
Intervention: Radiology specialist registrars interpreting images
Number of subjects: 25
Study: 8608441

Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 18
Study: 2773843

Group type: EXPERIMENTAL
Intervention: Oral iron therapy
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Anemic infants
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control infants and nonanemic, iron-deficient infants
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Iron deficiency progressing to anemia
Number of subjects: 196
Study: 1035149

Group type: EXPERIMENTAL
Intervention: Oral tetracycline in combination with a topical sodium sulfacetamide-sulfur-hydro-cortisone lotion
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group of 50 patients
Number of subjects: 95
Study: 31662210

Group type: EXPERIMENTAL
Intervention: Financial incentives for completing secondary prevention sessions
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130
Study: 28686772

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (20 U total in affected area)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 9
Study: 25395384

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 144
Study: 23861993

Group type: EXPERIMENTAL
Intervention: Fish oil (4 g/day for 12 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21287196

Group type: EXPERIMENTAL
Intervention: Strength trained individuals (L(opt) 9.7% BW)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Speed trained individuals (L(opt) 9.2% BW)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Physically active individuals (L(opt) 8.7% BW)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sedentary individuals (L(opt) 8.0% BW)
Number of subjects: 40
Study: 19718745

Group type: EXPERIMENTAL
Intervention: Continuous EMG monitoring plus visual facial observation (EMG group)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Visual facial observation only (control group)
Number of subjects: 96
Study: 17451642

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) for CFS
Number of subjects: 128
Study: 15483071

Group type: EXPERIMENTAL
Intervention: 25 g high‐isoflavone soy protein (SOY)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control diet (meat protein)
Number of subjects: 13
Study: 11666130

Group type: EXPERIMENTAL
Intervention: Nadroparin calcium followed by adjunctive oral aspirin for 6 months
Number of subjects: 172

Group type: COMPARATOR
Intervention: Full heparinization
Number of subjects: 172
Study: 9639862

Group type: EXPERIMENTAL
Intervention: Thinking about gender group's privileges
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thinking about gender group's disadvantages
Number of subjects: 0
Study: 8205854

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no amiodarone)
Number of subjects: 0
Study: 2531901

Group type: EXPERIMENTAL
Intervention: 5 mg ramipril once daily for 7 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo once daily for 7 days
Number of subjects: 8
Study: 31909554

Group type: EXPERIMENTAL
Intervention: 300 g/l PEG (drought stress)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Non-treatment (control)
Number of subjects: 2
Study: 30993601

Group type: EXPERIMENTAL
Intervention: Mindful Moms Training (MMT) for 8 weeks
Number of subjects: 220

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 220
Study: 28012633

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4mg/ml, 1ml) administered 15min before surgery
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4mg/ml, 1ml) administered 15min after surgery
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo administered 15min before and after surgery
Number of subjects: 90
Study: 24555998

Group type: EXPERIMENTAL
Intervention: HBV envelope‐expressing DNA vaccine (5 intramuscular injections at weeks 0, 8, 16, 40, and 44)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No vaccine (control group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: HBV envelope‐expressing DNA vaccine
Number of subjects: 70
Study: 23212717

Group type: EXPERIMENTAL
Intervention: Intensive diabetes mellitus treatment
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Conventional diabetes mellitus treatment
Number of subjects: 1015
Study: 22048910

Group type: EXPERIMENTAL
Intervention: Intensive training and help offered during BMT
Number of subjects: 999

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 999
Study: 19358927

Group type: EXPERIMENTAL
Intervention: crocetin (15 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ascorbic acid (3,000 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 16515100

Group type: EXPERIMENTAL
Intervention: OEFRP (orthodontic extrusion combined with fiberotomy and root planing)
Number of subjects: 20

Group type: COMPARATOR
Intervention: OE (orthodontic extrusion)
Number of subjects: 20
Study: 12625392

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure
Number of subjects: 22

Group type: COMPARATOR
Intervention: Traditional wet-to-dry/wet-to-wet technique
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 22
Study: 12585168

Group type: EXPERIMENTAL
Intervention: Colquhounia root tablet (CRT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Hormone or cytotoxic medicine (Control)
Number of subjects: 96
Study: 9584030

Group type: EXPERIMENTAL
Intervention: 50 mg of methadone with 5 visits per week
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 50 mg of methadone with fewer visits
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 80 mg of methadone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 5 visits per week
Number of subjects: 150

Group type: COMPARATOR
Intervention: 2 visits per week
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall HIV infection rate at entry
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Risk behaviors for AIDS
Number of subjects: 150
Study: 7624397

Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine and human epidermal growth factor
Number of subjects: 17

Group type: COMPARATOR
Intervention: Silver sulfadiazine (control)
Number of subjects: 17
Study: 2647605

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of porcine GIP (2 pmol.kg‐1.min‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 0
Study: 352210

Group type: EXPERIMENTAL
Intervention: Inactivated bivalent (A/NJ and A/Victoria) influenza vaccine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study: 31402745

Group type: EXPERIMENTAL
Intervention: Relational savoring intervention
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 63
Study: 31179779

Group type: EXPERIMENTAL
Intervention: FMX101 4%
Number of subjects: 363

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 363
Study: 28525512

Group type: EXPERIMENTAL
Intervention: Parecoxib (40 mg at the end of surgery and then every 12 hours for 3 days)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 620

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study: 25496767

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic radical cystectomy (RARC) with PLND
Number of subjects: 118

Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC) with PLND
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both RARC and ORC
Number of subjects: 118

Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 118
Study: 23691828

Group type: EXPERIMENTAL
Intervention: Single-column (with long line length) layout
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Multicolumn setting (with medium or short line length)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Interline spacing
Number of subjects: 210
Study: 21642242

Group type: EXPERIMENTAL
Intervention: Maximal exercise stress test after intermittent upper arm ischaemia (EST‐2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Maximal exercise stress test only (EST‐1)
Number of subjects: 20
Study: 19096945

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of sterile water
Number of subjects: 100

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 100
Study: 16449048

Group type: EXPERIMENTAL
Intervention: Lay health workers (LHWs) involved in TB control activities on farms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current local tuberculosis control programme
Number of subjects: 0
Study: 15504182

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 7.5 mg with sufentanil 5 microg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 15 mg
Number of subjects: 50
Study: 11783100

Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 34

Group type: COMPARATOR
Intervention: Kytril
Number of subjects: 34
Study: 9259608

Group type: EXPERIMENTAL
Intervention: Immunochemical method (ELISA) for detecting P. carinii antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brown rat (Rattus norvegicus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bank vole (Clethrionomys glareolus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: European water voles (Arvicola terrestris) and field voles (Microtus arvalis)
Number of subjects: 0
Study: 8388403

Group type: EXPERIMENTAL
Intervention: ile12-ANP (1.5 pmol/kg/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30972018

Group type: EXPERIMENTAL
Intervention: 30 mg fasudil
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 60 mg fasudil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fasudil (30 mg or 60 mg)
Number of subjects: 120
Study: 30049304

Group type: EXPERIMENTAL
Intervention: Desmopressin oral tablet (0.6 mg; 0.2 mg × 3) under fed conditions
Number of subjects: 104

Group type: COMPARATOR
Intervention: Desmopressin oral tablet (0.6 mg; 0.2 mg × 3) under fasted conditions
Number of subjects: 104
Study: 26723860

Group type: EXPERIMENTAL
Intervention: K2/Apex hip system
Number of subjects: 3
Study: 24351876

Group type: EXPERIMENTAL
Intervention: Peanuts with a variety of flavors (n = 50)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Peanuts with a single flavor (n = 25-26/group)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Participants at greater risk of cardiovascular disease
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Peanuts with any flavoring
Number of subjects: 151
Study: 23216861

Group type: EXPERIMENTAL
Intervention: Augmented Community Telerehabilitation Intervention (ACTIV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 19914369

Group type: EXPERIMENTAL
Intervention: EG 500 (500 mg of Campomanesia xanthocarpa)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: EG 250 (250 mg of Campomanesia xanthocarpa)
Number of subjects: 33

Group type: COMPARATOR
Intervention: CG (placebo capsules)
Number of subjects: 33
Study: 18715435

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 40
Study: 16427526

Group type: EXPERIMENTAL
Intervention: Physostigmine (PHYSO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 40
Study: 12663362

Group type: EXPERIMENTAL
Intervention: Textured replacement insoles in football boots
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional smooth insoles in football boots
Number of subjects: 17
Study: 10066008

Group type: EXPERIMENTAL
Intervention: Fluvoxamine combined with exposure
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo medication plus exposure
Number of subjects: 76

Group type: COMPARATOR
Intervention: Psychological panic management plus exposure
Number of subjects: 76

Group type: COMPARATOR
Intervention: Exposure alone
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Fluvoxamine plus exposure
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 76
Study: 8952328

Group type: EXPERIMENTAL
Intervention: Improved Estimated Ecological Daily Intake (EEDI) method for estimating daily intake of food contaminants and additives.
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Improved EEDI method incorporating contamination levels of foodstuffs.
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Improved EEDI method for estimating daily intake of environmental contaminants.
Number of subjects: 159
Study: 1802182

Group type: EXPERIMENTAL
Intervention: Betadine connection shield (Group 2, n = 22)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard management (Group 1, n = 25)
Number of subjects: 35
Study: 6478471

Group type: EXPERIMENTAL
Intervention: Acebutolol, 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Propranolol, 10 mg
Number of subjects: 12
Study: 30916625

Group type: EXPERIMENTAL
Intervention: Single use polyvinylchloride catheters
Number of subjects: 75

Group type: COMPARATOR
Intervention: Reused polyvinylchloride catheters
Number of subjects: 75
Study: 30101439

Group type: EXPERIMENTAL
Intervention: 10 mg TFV film
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 40 mg TFV film
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: TFV 1% gel
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo film
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Film users
Number of subjects: 78
Study: 27371905

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 25439165

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training for 3 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo WBV (sham WBV) for 3 weeks
Number of subjects: 18
Study: 23006462

Group type: EXPERIMENTAL
Intervention: Medical treatment for a variable period of 1-12 years
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fulminant hepatic failure (FHF) without liver transplantation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall mortality during the study period
Number of subjects: 40
Study: 19947406

Group type: EXPERIMENTAL
Intervention: Short-wave therapy included in rehabilitative program
Number of subjects: 49
Study: 17179770

Group type: EXPERIMENTAL
Intervention: N-3 polyunsaturated fatty acids (PUFAs) - 2 capsules containing 1 g of fish oil 3 times daily (n = 60)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo - 1 g of paraffin oil capsules (n = 62)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: N-3 polyunsaturated fatty acids (PUFAs) - open-label phase
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo - open-label phase
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: N-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: N-3 polyunsaturated fatty acids (PUFAs) - patients with baseline TG levels >10 g/L
Number of subjects: 122

Group type: COMPARATOR
Intervention: N-3 polyunsaturated fatty acids (PUFAs) vs. Placebo
Number of subjects: 122
Study: 15123223

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (SLM/FP) 50 microg and 500 microg Diskus, 1 inhalation twice daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Theophylline (THEO) plus fluticasone propionate (FP) 500 microg Diskus, 1 inhalation twice daily
Number of subjects: 80
Study: 11241808

Group type: EXPERIMENTAL
Intervention: 2D‐echo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 50
Study: 9678714

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (HDMP, 900-600 mg/m2 orally)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Conventional-dose prednisolone (2 mg/kg/day orally)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (HDMP)
Number of subjects: 166
Study: 8034783

Group type: EXPERIMENTAL
Intervention: Mouthrinse containing 0.4% zinc sulphate and 0.15% triclosan (mouthrinse 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control mouthrinse
Number of subjects: 0
Study: 2660553

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 667

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Sucralfate and Cimetidine
Number of subjects: 667
Study: 4913624

Group type: EXPERIMENTAL
Intervention: Histamine acid phosphate (1, 10, 40, and 80 mug/kg/hr)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pentagastrin (0.15, 1.5, 6.0, and 12.0 mug/kg/hr)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Histamine acid phosphate and Pentagastrin (comparison)
Number of subjects: 6
Study: 31764395

Group type: EXPERIMENTAL
Intervention: Patient decision aids
Number of subjects: 6376

Group type: EXPERIMENTAL
Intervention: Patient-clinician communication
Number of subjects: 6376

Group type: EXPERIMENTAL
Intervention: Nurse-facilitated communication interventions
Number of subjects: 6376
Study: 31477168

Group type: EXPERIMENTAL
Intervention: T‐DM1, lapatinib, and nab‐paclitaxel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Trastuzumab, pertuzumab, and paclitaxel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: T‐DM1, lapatinib, and nab‐paclitaxel (in ER-positive subset)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Trastuzumab, pertuzumab, and paclitaxel (in ER-positive subset)
Number of subjects: 30
Study: 28000311

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin (SCIG) 0.4 g/kg/week for 5 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG) 0.4 g/kg/day for 5 days
Number of subjects: 20
Study: 26555352

Group type: EXPERIMENTAL
Intervention: High-dose intradermal TIV
Number of subjects: 155
Study: 23820880

Group type: EXPERIMENTAL
Intervention: Closed Kinetic Chain (CKC) exercises
Number of subjects: 32

Group type: COMPARATOR
Intervention: Closed Kinetic Chain (CKC) exercises with additional hip strengthening exercises (Control group)
Number of subjects: 32
Study: 21573899

Group type: EXPERIMENTAL
Intervention: Drainage of the wound
Number of subjects: 803

Group type: COMPARATOR
Intervention: No drainage of the wound
Number of subjects: 803
Study: 19500421

Group type: EXPERIMENTAL
Intervention: Systematic Care Program for Dementia (SCPD)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 6